Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Texier

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
European Urology|May 22, 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed TomographyYohann Loriot, Matthieu Texier, Stéphane Culine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic CarcinomaMichel Ducreux, Romain Desgrippes, Yves Rinaldi, et al.
British Journal of Cancer|December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trialSophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.
ACS Nano|June 24, 2024
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical CancerCyrus Chargari, Pauline Maury, Matthieu Texier, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Lancet (London, England)|February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trialEric Baudin, Bernard Goichot, Alfredo Berruti, et al.
The Lancet. Oncology|July 28, 2020
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 studyDiane Goéré, Olivier Glehen, François Quenet, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
European Urology|May 22, 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed TomographyYohann Loriot, Matthieu Texier, Stéphane Culine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic CarcinomaMichel Ducreux, Romain Desgrippes, Yves Rinaldi, et al.
British Journal of Cancer|December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trialSophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.
ACS Nano|June 24, 2024
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical CancerCyrus Chargari, Pauline Maury, Matthieu Texier, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Lancet (London, England)|February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trialEric Baudin, Bernard Goichot, Alfredo Berruti, et al.
The Lancet. Oncology|July 28, 2020
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 studyDiane Goéré, Olivier Glehen, François Quenet, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Pageof 3